Histone deacetylase inhibitors suppress the inducibility of nuclear factor-κB by tumor necrosis factor-α receptor-1 down-regulation

Cancer Research

Volumn 66, Issue 10, 2006, Pages 5409-5418

  Imre, Gabriele ^a   Gekeler, Volker ^a   Leja, Astrid ^a   Beckers, Thomas ^a   Boehm, Markus ^a  

^a ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DEGRADATION; DNA BINDING; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA, NEOPLASM; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; I-KAPPA B KINASE; LUNG NEOPLASMS; MICE; MICE, NUDE; NF-KAPPA B; PHOSPHORYLATION; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33744938927     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4225     Document Type: Article

References (49)

1. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005;45:495-528.
2. Marks PA, Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005;4:549-51.
3. La Thangue NB. Histone deacetylase inhibitors and cancer therapy. J Chemother 2004;16 Suppl 4:64-7.
4. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004;91:137-68.
5. Villar-Garea A, Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents, Int J Cancer 2004;112:171-8.
6. Richon VM, Webb Y, Merger R, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A 1996;93:5705-8.
7. Joseph J, Mudduluru G, Antony S, Vashistha S, Ajitkumar P, Somasundaram K. Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene 2004;23:6304-15.
8. Wang S, Yan-Neale Y, Zeremski M, Cohen D. Transcription regulation by histone deacetylases. Novartis Found Symp 2004;259:238-45.
9. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 2004;101:540-5.
10. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
11. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF κB action regulated by reversible acetylation. Science 2001;293:1653-7.
12. Kiernan R, Bres V, Ng RW, et al. Post-activation turn-off of NF κB-dependent transcription is regulated by acetylation of p65. J Biol Chem 2003;278:2758-66.
13. Hu J, Colburn NH. Histone deacetylase inhibition down-regulates cyclin DI transcription by inhibiting nuclear factor-KB/p65 DNA binding. Mol Cancer Res 2005;3:100-9.
14. Baldwin AS, Jr. Series introduction: the transcription factor NF-κB and human disease. J Clin Invert 2001;1073-6.
15. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004;6:203-8.
16. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
17. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-8.
18. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Jr., Sledge GW, Jr. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17:3629-39.
19. Lind DS, Hochwald SN, Malaty J, et al. Nuclear factor-κB is upregulated in colorectal cancer. Surgery 2001;130:363-9.
20. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-47.
21. Yung L, Linch D. Hodgkin's lymphoma. Lancet 2003;361:943-51.
22. Anto RJ, Mukhopadhyay A, Shishodia S, Gairola CG, Aggarwal BB. Cigarette smoke condensate activates nuclear transcription factor-κB through phosphorylation and degradation of IκB(α): correlation with induction of cyclooxygenase-2. Carcinogenesis 2002;23:1511-8.
23. Shen Y, Rattan V, Sultana C, Kalra VK. Cigarette smoke condensate-induced adhesion molecule expression and transendothelial migration of monocytes. Am J Physiol 1996;270:H1624-33.
24. Wright JG, Christman JW. The role of nuclear factor κB in the pathogenesis of pulmonary diseases: implications for therapy. Am J Respir Med 2003;2:211-9.
25. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999;18:943-53.
26. Shimomoto H, Hasegawa Y, Nozaki Y, et al. Expression of tumor necrosis factor receptors in human lung cancer cells and normal lung tissues. Am J Respir Cell Mol Biol 1995;13:271-8.
27. Nakamura H, Hino T, Kato S, Shibata Y, Takahashi H, Tomoike H. Tumour necrosis factor receptor gene expression and shedding in human whole lung tissue and pulmonary epithelium. Eur Respir J 1996;9:1643-7.
28. Kim YH, Park JW, Lee JY, Kwon TK. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 2004;25:1813-20.
29. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004;23:6261-71.
30. Vanoosten RL, Moore JM, Karacay B, Griffith TS. Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biol Ther 2005;4:1104-12.
31. Sonnemann J, Gange J, Kumar KS, Muller C, Bader P, Beck JF. Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Invest New Drugs 2005;23:99-109.
32. Ling L, Cao Z, Goeddel DV. NF-κB-inducing kinase activates IKK-a by phosphorylation of Ser-176. Proc Natl Acad Sci U S A 1998;95:3792-7.
33. Yang J, Lin Y, Guo Z, et al. The essential role of MEKK3 in TNF-induced NF-κB activation. Nat Immunol 2001;2:620-4.
34. Arts J, de Schepper S, Van Emelen K. Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 2003;10:2343-50.
35. Blagosklonny MV, Robey R, Sackett DL, et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 2002;1:937-41.
36. Matsuyama A, Shimazu T, Sumida Y, et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 2002;21:6820-31.
37. Roy S, Packman K, Jeffrey R, Tenniswood M. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 2005;12:482-91.
38. Terui T, Murakami K, Takimoto R, et al. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res 2003;63:8948-54.
39. Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005;18:601-7.
40. Rahman MM, Kukita A, Kukita T, Shobuike T, Nakamura T, Kohashi O. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 2003;101:3451-9.
41. Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-κB activation and cellular proteasome activity. J Biol Chem 2001;276:44641-6.
42. Rundall BK, Denlinger CE, Jones DR. Combined histone deacetylase and NF-κB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 2004;136:416-25.
43. Mayo MW, Denlinger CE, Broad RM, et al. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-κB through the Akt pathway. J Biol Chem 2003;278:18980-9.
44. Leoni F, Zaliani A, Bertolini G, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A 2002;99:2995-3000.
45. Quivy V, Van Lint C. Regulation at multiple levels of NF-κB-mediated transactivation by protein acetylation. Biochem Pharmacol 2004;68:1221-9.
46. Schmitz ML, Mattioli I, Buss H, Kracht M. NF-κB: a multifaceted transcription factor regulated at several levels. Chembiochem 2004;5:1348-58.
47. Roychowdhury S, Baiocchi RA, Vourganti S, et al. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. J Natl Cancer Inst 2004;96:1447-57.
48. Dai Y, Rahmani M, Dent P, Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-κB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP down-regulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 2005;25:5429-44.
49. Adam E, Quivy V, Bex F, et al. Potentiation of tumor necrosis factor-induced NF-κB activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of IκBα. Mol Cell Biol 2003;23:6200-9.